AI-extracted from the 20-F filed 2026-02-24 — FY2025 (year ended December 31, 2025). Every figure is machine-verified against the filing text on SEC EDGAR.
Alcon achieved $10.3B in net sales for FY2025, driven by strong Surgical growth and strategic acquisitions including LumiThera, Cylite, Aurion Biotech, and BELKIN Vision.
Biggest Revenue Drivers
Surgical$5.8B
Offers implantable products, consumables and equipment for cataract, vitreoretinal, refractive and glaucoma surgeries with market-leading position globally.
Vision Care$4.6B
Comprises daily disposable, reusable and color-enhancing contact lenses and comprehensive ocular health products including dry eye and allergy relief.
Biggest Revenue Drivers
Total revenue: $10.3B
Surgical$5.8B
Offers implantable products, consumables and equipment for cataract, vitreoretinal, refractive and glaucoma surgeries with market-leading position globally.
Vision Care$4.6B
Comprises daily disposable, reusable and color-enhancing contact lenses and comprehensive ocular health products including dry eye and allergy relief.
Largest Expense Items
Research and development$990M
Investment in research and development with more than 2,100 associates dedicated to product innovation across optical design, material chemistry, and equipment platforms.
Margins: The filing does not provide specific gross margin or operating margin commentary for FY2025. However, the company states its strategy to leverage infrastructure and improve operating efficiencies to enhance core operating income margins over time through improved sales mix and supply chain initiatives.
Watch Items from the Filing
China represents approximately 6% of net sales in 2025, with expectation for percentage growth. However, increasingly challenging economic, political and legal environment, Volume-Based Procurement pricing pressures, and 'Made in China 2025' policies favoring domestic manufacturers create significant uncertainty and potential revenue impact.
Company carries substantial goodwill and intangible assets on balance sheet; recorded $45M in impairment charges in 2025 and $9M in 2024, indicating exposure to future write-downs if fair values decline.
Alcon announced intent to acquire STAAR Surgical in August 2025, but STAAR was unable to obtain necessary shareholder approvals to consummate the transaction, demonstrating execution risk on strategic acquisitions.
The company relies on single or limited sources of supply for key components (viscoelastics, active pharmaceutical ingredients, sterilization services). Past shortages in 2022-2023 affected contact lens business and resulted in delays and lost revenue.
Outstanding debt of $4.7B as of December 31, 2025 limits financial flexibility; recent interest rate increases have raised borrowing costs and may continue to do so, potentially affecting debt refinancing.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
5 transactions in ALC reported by 4 members of Congress under the STOCK Act, most recent trade Aug 5, 2026. Reported transactions, not recommendations.
About ALCON INC (ALC): stock profile, AI score and financials
ALCON INC (ALC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALC at 65.9/100 on a composite quality score built from its SEC filings, placing it at rank #442 of 2,925 stocks — the top 25% of the AI-ranked universe. ALC scores in the top quartile across earnings quality (92.3), institutional flow (87.1), revenue scale (86.1). Areas of concern include revenue growth (31.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), ALCON INC reports quarterly revenue of $10.4B, net income of $980.0M, an operating margin of 13.1%. Top institutional holders of ALC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Bank of New York Mellon, NORGES BANK, based on the most recent SEC filings. ALC trades on the NYSE exchange and files with the SEC under CIK 1167379. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALCON INC directly from SEC EDGAR.